This Biotech Just Got the Backing Big Money Waits For

With a $100M+ raise from biotech insiders and a pricing premium no one saw coming, this under-the-radar name might finally be stepping into the spotlight.

The key? Upcoming FDA milestones that could unlock serious upside.

Every big shift in energy starts the same way. The giants prove the model. Then a smaller company with the right edge captures the early growth.

Today, the giants are Tesla, Enphase, and Generac. They showed energy storage works. They proved that without batteries, solar and wind collapse the moment the sun sets or the wind dies.

Elon Musk even said storage will grow bigger than Tesla’s car business. Last year, the company deployed 31.4 GWh of energy storage.

But the real prize is ahead. The US storage market is expected to climb to $465 billion by 2030, a 75% jump from today’s $265 billion.

And there is a small US stock that is already surging. Revenue has grown by more than 200% year over year. Distributor orders are topping millions. And the market cap? Just $177 million.

While Trump’s new tariffs of up to 34% threaten to crush Chinese and Southeast Asian imports, this company’s US and Austrian supply chain puts it in the perfect position to benefit. Rivals get squeezed, while this stock gains ground.

The billionaires have already placed their bets on batteries. Musk. Gates. Bezos. Google. Even Robert Downey Jr.

The question is, will you place yours before Wall Street wakes up?

Unlock the name and symbol now to get the full story.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Wall Street tumbled on Friday after President Trump threatened a massive increase in tariffs on Chinese imports amid escalating tensions over rare earth exports, sparking fears of a renewed trade war.

Bristol Myers Squibb (NYSE: BMY) just made a move that’ll make you look twice at biotech.

The pharma heavyweight is buying Orbital Therapeutics for $1.5 billion, pulling itself deeper into the world of RNA science and cell therapy innovation.

If you’ve been watching the pharma shake-up lately, you know why this matters. Bristol Myers needs new blockbusters, and this deal gives it the science to build them.

A New Spin on CAR-T

Orbital’s star program, OTX-201, is designed to generate immune cells inside the body instead of in a lab — think faster, cheaper, and more scalable.

It’s the kind of innovation you don’t need a PhD to get excited about.

For Bristol Myers, it’s a pivot from maintaining what it has to creating what’s next. That’s where the real growth story starts to brew.

Building the Next Biotech Blueprint

The buyout also hands Bristol Myers a shiny new RNA and AI toolkit to engineer drugs faster and smarter.

If you’re betting on long-term innovation over short-term defense, this is the kind of move you cheer for.

Bristol Myers isn’t just playing catch-up in biotech. It’s quietly writing the script for what your next-generation medicine might look like.

Zillow Group (NASDAQ: ZG) is finally flirting with profitability after more than a decade of red ink.

The company’s mortgage business is booming, headcount is leaner, and revenue growth is back on the charts, giving investors a rare reason to smile.

But Wall Street’s mood didn’t stay sunny for long.

The stock soared 10 percent on earnings in September before dropping 20 percent when reality — and regulators — came knocking.

The FTC Crash Landing

Just when Zillow looked ready for its clean-slate moment, the FTC accused it of cutting an illegal deal with Redfin.

The agency says their partnership may have reduced competition and hurt renters, sending investors running for cover faster than you can say “open house.”

It’s too early to know how this lawsuit ends, but the headline alone was enough to cool off momentum and spook short-term traders who had already pocketed solid gains.

AI, Mortgages, and the Silver Lining

Despite the legal fog, Zillow’s core business looks more focused than ever.

Mortgage revenue is up 41 percent, and its app just became the first to integrate directly with ChatGPT — a feature that gives you real-time, AI-powered home searches without the usual app-hopping.

If you’re patient, this dip could turn into an entry point. Zillow might finally be turning its “clicks over cash” story into an actual profit plan.

This is it — your final chance to claim the new 5 Stocks Set to Double report before free access closes tonight.

Inside, you’ll find the 5 companies our analysts believe could deliver standout gains as market momentum shifts into 2025.

These aren’t hype-driven plays — they’re backed by strong balance sheets, rising earnings, and catalysts that could fuel sustained growth.

But once the clock strikes midnight, this report goes offline.

Don’t let hesitation cost you potential profits.

Download your free copy now and see the 5 stocks poised to lead the next big move.

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

Papa John’s International (NASDAQ: PZZA) is thinking far beyond its usual pizza box.

India has officially earned a top spot on the chain’s global priority list, as the company looks to spice up international growth and cut back on its North America dependency.

You can already picture it: less pepperoni, more paneer, and an entire market of customers who treat pizza like a festival food.

Local Taste, Global Strategy

The brand’s India rollout isn’t just about dropping stores; it’s about crafting a menu built for the country’s massive vegetarian population.

From loaded veggie specials to spice-forward sauces, Papa John’s is going all in on local flavor.

The math is simple. India’s booming middle class, digital delivery boom, and appetite for affordable indulgence make it one of the hottest playgrounds for fast-food innovation.

Pizza with a Purpose

For you, this means Papa John’s isn’t just chasing global headlines. It’s trying to future-proof its business by blending local culture with international scale.

If Papa John’s can pull this off, it won’t just sell more pizzas. It’ll prove that the secret ingredient in global expansion is knowing what people actually want to eat.

👉 Click here to get our closing report to your cell for free!

Quoin Pharmaceuticals Ltd [QNRX] $20.50 (+151.23%)

Quoin surged after announcing a private placement of up to $104.5M with major healthcare investors, priced at a premium and structured around key regulatory milestones.

Safe & Green Holdings Corp [SGBX] $6.24 (+92.59%)

Safe & Green rallied after regaining Nasdaq compliance and reducing dilution risks through a successful restructuring and reverse split.

Protagonist Therapeutics Inc [PTGX] $87.00 (+29.77%)

Protagonist spiked after reports that Johnson & Johnson is in acquisition talks to strengthen their biotech partnership.

Xenetic Biosciences Inc [XBIO] $6.33 (-33.09%)

Xenetic tumbled after pricing a $4.5 million public offering at a discount $6.12 per share, sparking dilution concerns among investors.

Venture Global Inc [VG] $9.45 (-24.94%)

Venture Global plunged after losing an arbitration case against BP, raising fears of billions in potential damages from other pending disputes.

Usana Health Sciences Inc [USNA] $20.26 (-23.11%)

USANA dropped after issuing weaker-than-expected preliminary Q3 results, citing soft sales and lower Brand Partner productivity.

The numbers do not lie.

The US energy storage industry is already booming. From $265 billion today, it is projected to reach $465 billion by 2030. That is 75% growth in just a few short years.

And electricity bills are rising fast. Since 2024, US power costs are up 6.5%. Analysts see another 8% jump nationwide by 2030, with some states facing 30% to 60% spikes. Families need backup. Businesses need resilience. Utilities need stability.

The giants are capitalizing. Tesla booked more than $10 billion in storage revenue. Enphase pulled in $356 million in a single quarter. Generac sold hundreds of millions.

But here is the opening. One US battery stock is still tiny. It trades at just $177 million but already posted three straight record quarters. Revenue has more than tripled year over year, and multimillion-dollar orders keep building.

Now add Trump’s new tariff bombshell. Starting in 2026, imported batteries could face penalties of up to 34%. Enphase has already warned margins will drop by 6 to 8 points. But this small company sources from the US and Austria. Instead of pain, tariffs become profit.

This is exactly the kind of setup early investors dream about. Big market. Fast growth. A small cap positioned to win while giants stumble.

Click here to learn the details before the crowd catches on.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.